Besides, EA was also shown as an inhibitor of multiple myeloma [117–119], renal cancer, as well as of chronic lymphocytic leukemia cell survival [120] by interfering with the Wnt/beta-catenin signaling pathway [121]. This evidence concerns the gene CTNNB1 and B-cell chronic lymphocytic leukemia.